Recent News

• 06.12.2025 - Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 05.29.2025 - Autolus Therapeutics to Participate in Upcoming Investor Conferences
• 05.23.2025 - Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
• 05.14.2025 - Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
• 05.08.2025 - Financial results for the First Quarter 2025 – conference call
• 05.08.2025 - Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Recent Filings

• 06.02.2025 - 8-K Current report
• 06.02.2025 - EX-99.1 EX-99.1
• 05.30.2025 - 8-K Current report
• 05.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.15.2025 - EFFECT Notice of Effectiveness
• 05.15.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]